Familial hypercholesterolemia: current treatment and advances in management

Roeland Huijgen; Maud N. Vissers; Joep C. Defesche; Peter J. Lansberg; John J. P. Kastelein; Barbara A. Hutten

doi:https://doi.org/10.1586/14779072.6.4.567

Familial hypercholesterolemia: current treatment and advances in management

Roeland Huijgen, Maud N. Vissers, Joep C. Defesche, Peter J. Lansberg, John J. P. Kastelein, Barbara A. Hutten

Research output: Contribution to journal › Article › Academic › peer-review

65 Citations (Scopus)

Abstract

Heterozygous familial hypercholesterolemia is associated with elevated levels of LDL-cholesterol and the development of premature cardiovascular disease. The condition is considerably under-diagnosed and under-treated. Statins are the first choice treatment for all patients with heterozygous familial hypercholesterolemia. For those patients who do not reach their treatment target or who are unable to use adequate statin dose, several alternative treatment modalities can be used, either as add-on therapy or as monotherapy. In this review the various treatment options are discussed

Original language	English
Pages (from-to)	567-581
Journal	Expert Review of Cardiovascular Therapy
Volume	6
Issue number	4
DOIs	https://doi.org/10.1586/14779072.6.4.567
Publication status	Published - 2008

Access to Document

https://doi.org/10.1586/14779072.6.4.567

Cite this

@article{cd55035c845343c2979e8f5ddabe926b,

title = "Familial hypercholesterolemia: current treatment and advances in management",

abstract = "Heterozygous familial hypercholesterolemia is associated with elevated levels of LDL-cholesterol and the development of premature cardiovascular disease. The condition is considerably under-diagnosed and under-treated. Statins are the first choice treatment for all patients with heterozygous familial hypercholesterolemia. For those patients who do not reach their treatment target or who are unable to use adequate statin dose, several alternative treatment modalities can be used, either as add-on therapy or as monotherapy. In this review the various treatment options are discussed",

author = "Roeland Huijgen and Vissers, {Maud N.} and Defesche, {Joep C.} and Lansberg, {Peter J.} and Kastelein, {John J. P.} and Hutten, {Barbara A.}",

year = "2008",

doi = "https://doi.org/10.1586/14779072.6.4.567",

language = "English",

volume = "6",

pages = "567--581",

journal = "Expert Review of Cardiovascular Therapy",

issn = "1477-9072",

publisher = "Taylor & Francis",

number = "4",

}

TY - JOUR

T1 - Familial hypercholesterolemia: current treatment and advances in management

AU - Huijgen, Roeland

AU - Vissers, Maud N.

AU - Defesche, Joep C.

AU - Lansberg, Peter J.

AU - Kastelein, John J. P.

AU - Hutten, Barbara A.

PY - 2008

Y1 - 2008

N2 - Heterozygous familial hypercholesterolemia is associated with elevated levels of LDL-cholesterol and the development of premature cardiovascular disease. The condition is considerably under-diagnosed and under-treated. Statins are the first choice treatment for all patients with heterozygous familial hypercholesterolemia. For those patients who do not reach their treatment target or who are unable to use adequate statin dose, several alternative treatment modalities can be used, either as add-on therapy or as monotherapy. In this review the various treatment options are discussed

AB - Heterozygous familial hypercholesterolemia is associated with elevated levels of LDL-cholesterol and the development of premature cardiovascular disease. The condition is considerably under-diagnosed and under-treated. Statins are the first choice treatment for all patients with heterozygous familial hypercholesterolemia. For those patients who do not reach their treatment target or who are unable to use adequate statin dose, several alternative treatment modalities can be used, either as add-on therapy or as monotherapy. In this review the various treatment options are discussed

U2 - https://doi.org/10.1586/14779072.6.4.567

DO - https://doi.org/10.1586/14779072.6.4.567

M3 - Article

C2 - 18402545

SN - 1477-9072

VL - 6

SP - 567

EP - 581

JO - Expert Review of Cardiovascular Therapy

JF - Expert Review of Cardiovascular Therapy

IS - 4

ER -